MIL OSI Translation. Region: Germany / Deutschland –
Source: BayerPhase III CHRONOS-3 Study in Patients with Relapsed Indolent Non-Hodgkin’s Lymphoma (iNHL) Receiving One or More Lines of Previous Treatment Achieves Primary Endpoint / Safety and Tolerance Observed in the Study Substantially Consistent previously published data on the individual components of the combination; No new safety signals identified / Copanlisib is already approved in the USA as part of an accelerated procedure based on the Phase II study CHRONOS-1 and the overall response rate observed there in 104 adult patients with relapsed follicular lymphoma (FL)
EDITOR’S NOTE: This article is a translation. Apologies should the grammar and / or sentence structure not be perfect.